GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Lianhuan Pharmaceutical Co Ltd (SHSE:600513) » Definitions » Stock Based Compensation

Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Stock Based Compensation : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Jiangsu Lianhuan Pharmaceutical Co Stock Based Compensation?

Jiangsu Lianhuan Pharmaceutical Co's Stock Based Compensation for the three months ended in Mar. 2024 was ¥0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0 Mil.


Jiangsu Lianhuan Pharmaceutical Co Stock Based Compensation Historical Data

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Lianhuan Pharmaceutical Co Stock Based Compensation Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Jiangsu Lianhuan Pharmaceutical Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.


Jiangsu Lianhuan Pharmaceutical Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Jiangsu Lianhuan Pharmaceutical Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Business Description

Traded in Other Exchanges
N/A
Address
No. 21 Wenfeng Road, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225009
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs.
Executives
Chu Qing Song senior management
Xia Chun Lai Director
Pan He Ping Directors, senior managers
Niu Ben senior management
Wu Wen Ge Director
Zhu Yong Jun senior management
Qian Zhen Hua Director
Shen Yi senior management
Huang Wen Tao senior management
Zhou Jun senior management
Tu Bin senior management
Qin Xiong Jian senior management

Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Headlines

No Headlines